Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

recombinant human papillomavirus nonavalent vaccine

View Patient Information
A non-infectious, recombinant, nonavalent vaccine prepared from highly purified virus-like particles (VLPs) comprised of the major capsid (L1) proteins from human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, and 58, with active immunizing activity. Upon administration, the recombinant HPV nonavalent vaccine activates the immune system to produce antibodies against the 9 HPV types. This protects against HPV infection and HPV-related cancers. Altogether, HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 account for the majority of the HPV types that cause cervical, vulvar, vaginal and anal cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:nonavalent HPV recombinant vaccine
nonavalent HPV VLP vaccine
nonavalent human papillomavirus recombinant vaccine
recombinant HPV nonavalent vaccine
recombinant human papillomavirus 9-valent vaccine
US brand name:Gardasil 9
Code name:V503
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search